Lantheus Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Lantheus Holdings, Inc. (LNTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $49.19 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-26
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-09-30 was $2.35.
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-06-30 was $0.99, a 82.48% decline year-over-year.
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-06-30 was $5.65.
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $49.19, a 25.29% increase from fiscal 2024.
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $39.26, a 9.08% decline from fiscal 2023.
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $43.18.
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $5.67.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $49.19 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $39.26 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $43.18 10-K · filed 2026-02-26 | |||
| 2020-12-31 | $5.67 10-K · filed 2021-02-25 | |||
| 2016-12-31 | $1.44 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $1.44 10-K · filed 2017-02-23 | |||
| 2015-09-30 | $2.35 10-Q · filed 2015-11-04 | $1.44 10-Q · filed 2015-11-04 | ||
| 2015-06-30 | $0.99 10-Q · filed 2015-08-05 | $1.42 10-Q · filed 2015-08-05 | ||
| 2014-12-31 | $1.70 10-K · filed 2016-03-02 | |||
| 2014-09-30 | $2.08 10-Q · filed 2015-11-04 | |||
| 2014-06-30 | $5.65 10-Q · filed 2015-08-05 | $5.84 10-Q · filed 2015-08-05 | ||
| 2013-12-31 | $2.45 10-K · filed 2016-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |